Literature DB >> 26814372

HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.

Haitao Hu1, Fengliang Liu1, Jerome Kim2, Silvia Ratto-Kim3.   

Abstract

HIV causes infection and progressive depletion of human CD4 T cells. Emerging data have shown that antigen-specific CD4 T-cell subsets manifest differential susceptibility to HIV, potentially leading to pathogen-specific immune failure and opportunistic infections. This concept was recently explored in context of vectors utilized in HIV vaccine trials, and the data suggest that adenovirus type 5(Ad5)-specific CD4 T cells elicited by Ad5-HIV vaccine may be particularly susceptible to HIV, potentially rendering Ad5 vaccine recipients susceptible to HIV acquisition. We here examined recent data regarding the HIV susceptibility of antigen-specific CD4 T cells induced during infection or HIV vaccination and discussed its potential impact on HIV acquisition risk posed by HIV vaccination.

Entities:  

Keywords:  CD4 T cells; HIV susceptibility; HIV vaccine; antigen specificity; pathogenesis

Mesh:

Substances:

Year:  2016        PMID: 26814372      PMCID: PMC4955395          DOI: 10.1586/14760584.2016.1147354

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  75 in total

1.  Safety profile of recombinant canarypox HIV vaccines.

Authors:  Guy de Bruyn; Anthony J Rossini; Ya-Lin Chiu; Drienna Holman; Marnie L Elizaga; Sharon E Frey; Donald Burke; Thomas G Evans; Lawrence Corey; Michael C Keefer
Journal:  Vaccine       Date:  2004-01-26       Impact factor: 3.641

Review 2.  HIV-1 pathogenesis.

Authors:  Mario Stevenson
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

Review 3.  Poxvirus vector-based HIV vaccines.

Authors:  Giuseppe Pantaleo; Mariano Esteban; Bertram Jacobs; Jim Tartaglia
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

4.  Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses.

Authors:  Karin Loré; William C Adams; Menzo J E Havenga; Melissa L Precopio; Lennart Holterman; Jaap Goudsmit; Richard A Koup
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

5.  Pathogen-specific T cell depletion and reactivation of opportunistic pathogens in HIV infection.

Authors:  Christof Geldmacher; Richard A Koup
Journal:  Trends Immunol       Date:  2012-03-05       Impact factor: 16.687

6.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

7.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

Review 8.  Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors.

Authors:  Genoveffa Franchini; Sanjay Gurunathan; Lynn Baglyos; Stanley Plotkin; Jim Tartaglia
Journal:  Expert Rev Vaccines       Date:  2004-08       Impact factor: 5.217

9.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

10.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962

View more
  2 in total

1.  Strength of T cell signaling regulates HIV-1 replication and establishment of latency.

Authors:  Matthew Gagne; Daniel Michaels; Gillian M Schiralli Lester; Suryaram Gummuluru; Wilson W Wong; Andrew J Henderson
Journal:  PLoS Pathog       Date:  2019-05-22       Impact factor: 6.823

2.  Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.

Authors:  Sarah Auclair; Fengliang Liu; Qingli Niu; Wei Hou; Gavin Churchyard; Cecilia Morgan; Nicole Frahm; Sorachai Nitayaphan; Punnee Pitisuthithum; Supachai Rerks-Ngarm; Jason T Kimata; Lynn Soong; Genoveffa Franchini; Merlin Robb; Jerome Kim; Nelson Michael; Haitao Hu
Journal:  PLoS Pathog       Date:  2018-02-23       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.